Daiichi Sankyo, Waiv partner for ADC biomarkers

Daiichi Sankyo has entered into a collaboration with Paris-based Waiv intended at digital pathology biomarker discovery for an ADC programme. The platform will be applied to identify potential biomarkers linked to treatment response prior to upcoming trial phases. Waiv operates an international data network, connecting academic institutions, hospitals. Credit: Gorodenkoff / Shutterstock.com. Daiichi Sankyo has entered a collaboration with France-based Waiv, which aims to lead digital pathology biomarker discovery for an antibody-drug conjugate (ADC) programme. Waiv will use its computational pathology platform to work with early phase data, which will involve analysis of tumour microenvironments using haematoxylin and eosin (H&E),…

Source: Pharmaceutical Technology